1354945-69-9

Basic information

• Product Name: 2-[[(3aR,4S,6R,6aS)-6-(7-azanyl-5-propylsulfanyl-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy]ethanol
• Synonyms: 2-[[(3aR,4S,6R,6aS)-6-(7-azanyl-5-propylsulfanyl-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy]ethanol;Ticagrelor Impurity 7;Ticagrelor Impurity 32;Ticagrelor Related Compound 59
• CAS NO: 1354945-69-9
• Molecular Formula: C₁₄H₂₀ClN₅O₄S
• Molecular Weight: 410.49114
• EINECS: -0
• Mol File: 1354945-69-9.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-[[(3aR,4S,6R,6aS)-6-(7-azanyl-5-propylsulfanyl-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy]ethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[[(3aR,4S,6R,6aS)-6-(7-azanyl-5-propylsulfanyl-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy]ethanol(1354945-69-9)
• EPA Substance Registry System: 2-[[(3aR,4S,6R,6aS)-6-(7-azanyl-5-propylsulfanyl-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy]ethanol(1354945-69-9)

Safety Data

• Hazardous Substances Data: 1354945-69-9(Hazardous Substances Data)

Usage

Description

2-[[(3aR,4S,6R,6aS)-6-(7-azanyl-5-propylsulfanyl-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy]ethanol is a complex organic compound with a unique molecular structure. It is characterized by its stereochemistry, which includes four chiral centers (3aR, 4S, 6R, 6aS) and a heterocyclic ring system. The compound features a triazolopyrimidine core, a cyclopentane ring, and an ethyloxy chain, which contribute to its potential applications in various fields.

Uses

Used in Pharmaceutical Industry:
2-[[(3aR,4S,6R,6aS)-6-(7-azanyl-5-propylsulfanyl-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy]ethanol is used as an intermediate in the synthesis of metabolites of Ticagrelor (T437700). Ticagrelor is the first reversible oral P2Y12 receptor antagonist, which provides faster, greater, and more consistent ADP-receptor inhibition than Clopidogrel. 2-[[(3aR,4S,6R,6aS)-6-(7-azanyl-5-propylsulfanyl-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy]ethanol plays a crucial role in the development of new therapeutic agents for the treatment of cardiovascular diseases.
Used in Chemical Research:
Due to its unique molecular structure and stereochemistry, 2-[[(3aR,4S,6R,6aS)-6-(7-azanyl-5-propylsulfanyl-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy]ethanol can be utilized in chemical research for the development of novel compounds with potential applications in various fields, such as pharmaceuticals, materials science, and agrochemicals. Its synthesis and modification can lead to the discovery of new molecules with improved properties and functionalities.
Used in Drug Development:
The compound's structural features make it a promising candidate for drug development, particularly in the design of new therapeutic agents targeting specific biological receptors or enzymes. Its heterocyclic core and functional groups can be exploited to modulate its interactions with biological targets, potentially leading to the development of more effective and selective drugs.

Upstream product

• 946855-77-2 4,6-dichloro-5-[(E)-2-(4-phenyl)diazenyl]-2-(propylsulfanyl)pyrimidine 
• 145783-12-6 4,6-dihydroxy-2-(propylsulfanyl)pyrimidine 
• 1444301-60-3 (1S,2S,3R,5S)-3-amino-5-(2-hydroxyethoxy)cyclopentane-1,2-diol 
• 4099-85-8 methyl 2,3-O-isopropylidene-D-ribofuranoside 
• 1444301-56-7 tert-butyl ((3aS,4R,6S,6aR)-6-(2-(tert-butoxy)ethoxy)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)carbamate 
• 324535-98-0 tert-butyl ((3aS,4R,6S,6aR)-6-hydroxy-2,2-dimethyltetrahydro-3aH-cyclopenta[d]-[1,3]dioxol-4-yl)carbamate 
• 10257-32-6 D-ribose 
• 155855-53-1 (3aR,4S,6R,6aS)-6-(benzylamino)-2,2-dimethyltetrahydro-3ah-cyclopenta-[d][1,3]-dioxol-4-ol 
• 155855-51-9 tetrahydro-2,2-dimethyl-6-phenylmethyl-(3aS,4S,7R,7aS)-4,7-methano-4H-1,3-dioxolo[4,5-d][1,2]oxazine 
• 345898-95-5 N-(((4S,5R)-2,2-dimethyl-5-vinyl-1 ,3-dioxolan-4-yl)methylene)-1-phenylmethanamine oxide 
• 155934-55-7 (4R,5R)-2,2-dimethyl-5-vinyl-[1,3]dioxolane-4-carbaldehyde 
• 78341-96-5 (3aS,4S,6aR)-4-(bromomethyl)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole 
• 81026-76-8 ((3aR,4R,6aR)-6-methoxy-2,2-dimethyl-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl methanesulfonate 
• 4137-56-8 ((3aR,4R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl 4-methylbenzenesulfonate 

Downstream Products

• 274693-27-5 ticagrelor 

Relevant articles and documents

An NMR and DFT investigation on the interconversion of 9-substituented-N 6-hydrazone-8-azaadenine derivatives: proton migration or conformational isomerization?

A newly synthesized N6-arylhydrazone-8-azaadenine derivatives (1) showed significant differences in NMR spectra with previously synthesized analogues, specifically, the hydrogens of N1’H and C3’H in all the titled compounds showed two groups of signals in their 1H-NMR spectra. In order to investigate whether the duplication of proton signals were related to a mixture of conformational isomers which rotated around C-N1’ bond or configurational isomers which resulted from proton migration, variable temperature NMR and 2D-NOESY experiments were carried out in conjunction with density function theory (DFT) calculations at the B3LYP/6-311G (d,p)//B3LYP/6-31G (d,p) level. The results indicated that it was the conformational isomerism rather than hydrogen transfer that induced the reproduction of proton signals, which was attributed to lower barrier energy and larger rate constant of the former process.

A [...] preparation method and intermediate

The present invention relates to a preparation method and an intermediate of ticagrelor. The preparation method comprises that a compound represented by a formula VIII and a compound represented by a formula VII or a salt thereof as raw materials to carry out a reaction, and the obtained intermediate is subjected to acetonylidene protection group removing, optionally substituted azobenzene protection group removing, and cyclization, and then reacts with a compound represented by a formula II or a salt thereof to prepare the ticagrelor. The preparation method of the present invention has characteristics of short step, high total yield, mild reaction conditions and simple post-treatment, and is suitable for industrial production.

6-hydrazone radical-8-aza-purine compound and preparing method and application thereof

The invention relates to a 6-hydrazone radical-8-aza-purine compound and a preparing method and an application thereof and belongs to the fields of preparation of novel compounds and medicine application. The general molecular formula of the compound is shown in the description, wherein R1 is hydroxide radical, methylol group and hydroxyethoxy, R2 is hydrogen, hydroxide radical, and fluorine, R3 is methyl, ethyl, propyl and 3,3-trifluoropropyl group, and R4 is aryl group, substitutional aryl group, ceteroary, and substitutional ceteroary. A midbody is used as reaction substrate, wherein the formula of the midbody is shown in the description, the midbody and a hydrazine and aldehydes compound are subjected to a condensation reaction, and the 6-hydrazone radical-8-aza-purine compound is obtained. According to the novel 6-hydrazone radical-8-aza-purine compound, the antiplatelet aggregation activity is high, the bleeding side effect is low, and the compound can be used for preparing the antiplatelet aggregation medicine and preventing and treating the related thrombotic disease.